BioCorRx Inc. (BICX): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
BioCorRx Inc. (BICX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Resignation of Director On August 31, 2026, Kate Beebe DeVarney, Ph.D. submitted her resignation from her position as a mem
How this was made
The 30-second read
Why it matters
The filing provides the first public notice of the board change, a standard corporate governance disclosure.
Market read
Limited impact; primarily of interest to existing shareholders monitoring governance.
What to watch
Potential upcoming board reshuffle or strategic shift not yet announced.
Background
SEC Form 8‑K filing reports a director resignation and related board updates.
Ticker impact
Director Kate Beebe DeVarney resigned effective August 31, 2026, as disclosed in the 8‑K filing.
minimal short‑term movement expected
Director resignations are routine corporate actions with limited market effect.
Market effects
none
none
none
Counterpoint
The resignation could signal internal disagreements not disclosed publicly.
Key entities
- companyBioCorRx Inc.
Biopharmaceutical company filing the 8‑K.
- personKate Beebe DeVarney, Ph.D.
Resigning director.





